International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

European Commission Approves SPEVIGO® (spesolimab) for Generalized Pustular Psoriasis (GPP) Flares

BI SPEVIGO graphic

Boehringer Ingelheim’s spesolimab was granted conditional marketing authorization from the European Commission (EC) to treat generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. This conditional approval is based on Phase II clinical trial results for EFFISAYIL® 1. Carinne Brouillon, Member of the Board of Managing Directors responsible for Human Pharma, Boehringer Ingelheim stated, “We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases, which we are investigating in further clinical trials.”Boehringer Ingelheim’s spesolimab was granted conditional marketing authorization from the European Commission (EC) to treat generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. This conditional approval is based on Phase II clinical trial results for EFFISAYIL® 1. Carinne Brouillon, Member of the Board of Managing Directors responsible for Human Pharma, Boehringer Ingelheim stated, “We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases, which we are investigating in further clinical trials.”

Boehringer Ingelheim A Value Through Innovation

Categories

Tags

Recent Posts

Bachelez - New President Announcement

IPC Appoints New President for 2023

Think Tank Congress

Focus on Psoriasis: A Report from the 2022 IPC Think Tank – Miami

IPC Volunteer of the year 2022

Meet Our 2022 Volunteers of the Year

Also Read

Blog -Expert Insights-Maskin-Graphic
Biologics

Access to Biologics in Argentina: Rethinking Time to PASI 90

Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.